Literature DB >> 23242744

In silico identification of novel and selective monoamine oxidase B inhibitors.

Kemal Yelekçi1, Bora Büyüktürk, Nurdan Kayrak.   

Abstract

Monoamine oxidases (MAO) A and B are flavin adenine dinucleotides containing enzymes bound to the mitochondrial outer membranes of the cells of the brain, liver, intestine, and placenta, as well as platelets. Recently, selective MAO-B inhibitors have received increasing attention due to their neuroprotective properties and the multiple roles they can play in the therapy of neurodegenerative disorders. This study was based on 10 scaffolds that were selected from more than a million lead compounds in the ZINCv12 lead library for their structural and physicochemical properties which inhibit MAO-B. Utilizing ZINC and Accelrys 3.1 fragment-based libraries, which contain about 400 thousand fragments, we generated 200 potential candidates. GOLD, LibDock, and AutoDock 4.02 were used to identify the inhibition constants and their position in the active sites of both MAO isozymes. The dispositions of the candidate molecules within the organism were checked with ADMET PSA 2D (polar surface area) against ADMET AlogP98 (the logarithm of the partition coefficient between n-octanol and water). The MAO-B inhibition activities of the candidates were compared with the properties of rasagiline which is known to be a selective inhibitor of MAO-B.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23242744     DOI: 10.1007/s00702-012-0954-0

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  18 in total

1.  ZINC--a free database of commercially available compounds for virtual screening.

Authors:  John J Irwin; Brian K Shoichet
Journal:  J Chem Inf Model       Date:  2005 Jan-Feb       Impact factor: 4.956

Review 2.  The therapeutic potential of monoamine oxidase inhibitors.

Authors:  Moussa B H Youdim; Dale Edmondson; Keith F Tipton
Journal:  Nat Rev Neurosci       Date:  2006-04       Impact factor: 34.870

3.  Docking of novel reversible monoamine oxidase-B inhibitors: efficient prediction of ligand binding sites and estimation of inhibitors thermodynamic properties.

Authors:  K Yelekçi; O Karahan; M Toprakçi
Journal:  J Neural Transm (Vienna)       Date:  2007-03-31       Impact factor: 3.575

Review 4.  Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.

Authors:  Orly Weinreb; Tamar Amit; Orit Bar-Am; Moussa B H Youdim
Journal:  Prog Neurobiol       Date:  2010-06-19       Impact factor: 11.685

Review 5.  Biochemistry and genetics of monoamine oxidase.

Authors:  W Weyler; Y P Hsu; X O Breakefield
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

6.  New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.

Authors:  Nesrin Gökhan-Kelekçi; Semra Koyunoğlu; Samiye Yabanoğlu; Kemal Yelekçi; Ozen Ozgen; Gülberk Uçar; Kevser Erol; Engin Kendi; Akgül Yeşilada
Journal:  Bioorg Med Chem       Date:  2008-12-03       Impact factor: 3.641

7.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

8.  Molecular docking of inhibitors into monoamine oxidase B.

Authors:  William T Harkcom; David R Bevan
Journal:  Biochem Biophys Res Commun       Date:  2007-06-18       Impact factor: 3.575

9.  Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.

Authors:  Frantisek Hubálek; Claudia Binda; Min Li; Yaacov Herzig; Jeffrey Sterling; Moussa B H Youdim; Andrea Mattevi; Dale E Edmondson
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

10.  Structure of human monoamine oxidase A at 2.2-A resolution: the control of opening the entry for substrates/inhibitors.

Authors:  Se-Young Son; Jichun Ma; Youhei Kondou; Masato Yoshimura; Eiki Yamashita; Tomitake Tsukihara
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

View more
  3 in total

1.  Computational Chemistry and Molecular Modeling of Reversible MAO Inhibitors.

Authors:  Kemal Yelekçi; Safiye Sağ Erdem
Journal:  Methods Mol Biol       Date:  2023

Review 2.  Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening Methodologies.

Authors:  Katarina Nikolic; Lazaros Mavridis; Teodora Djikic; Jelica Vucicevic; Danica Agbaba; Kemal Yelekci; John B O Mitchell
Journal:  Front Neurosci       Date:  2016-06-10       Impact factor: 4.677

Review 3.  A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.

Authors:  Wolfgang H Jost
Journal:  J Neural Transm (Vienna)       Date:  2022-02-02       Impact factor: 3.850

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.